H. Alachkar and R. Santhanam, SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome, Journal of Clinical Investigation, vol.124, issue.4, pp.1512-1536, 2014.
DOI : 10.1172/JCI70921DS1

L. Albiges and J. Guegan, MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array, Clinical Cancer Research, vol.20, issue.13, pp.3411-3432, 2014.
DOI : 10.1158/1078-0432.CCR-13-2173

URL : https://hal.archives-ouvertes.fr/hal-01064619

D. C. Allred, Estrogen and progesterone receptors as predictive markers for breast cancer and DCIS, 2008.

D. C. Allred and J. M. Harvey, Prognostic and predictive factors in breast cancer by immunohistochemical analysis, Mod Pathol, vol.11, issue.2, pp.155-68, 1998.

S. Amatschek and U. Koenig, Tissue-Wide Expression Profiling Using cDNA Subtraction and Microarrays to Identify Tumor-Specific Genes, Cancer Research, vol.64, issue.3, pp.844-56, 2004.
DOI : 10.1158/0008-5472.CAN-03-2361

M. B. Amin and P. Tamboli, Prognostic Impact of Histologic Subtyping of Adult Renal Epithelial Neoplasms, The American Journal of Surgical Pathology, vol.26, issue.3, pp.281-91, 2002.
DOI : 10.1097/00000478-200203000-00001

S. Arnold and E. Mira, Forced Expression of MMP9 Rescues the Loss of Angiogenesis and Abrogates Metastasis of Pancreatic Tumors Triggered by the Absence of Host SPARC, Experimental Biology and Medicine, vol.233, issue.7, pp.860-73, 2008.
DOI : 10.3181/0801-RM-12

S. A. Arnold and R. A. Brekken, SPARC: a matricellular regulator of tumorigenesis, Journal of Cell Communication and Signaling, vol.6, issue.180, pp.3-4, 2009.
DOI : 10.1007/s12079-009-0072-4

M. Atkins and M. Regan, Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer, Clinical Cancer Research, vol.11, issue.10, pp.3714-3735, 2005.
DOI : 10.1158/1078-0432.CCR-04-2019

P. J. Barth and R. Moll, Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast, Virchows Archiv, vol.125, issue.5, pp.532-538, 2005.
DOI : 10.1007/s00428-005-1256-9

B. Bierie and H. L. Moses, Tumour microenvironment: TGF??: the molecular Jekyll and Hyde of cancer, Nature Reviews Cancer, vol.274, issue.7, pp.506-526, 2006.
DOI : 10.1038/nrc1926

B. Billemont and J. B. Meric, [Angiogenesis and renal cell carcinoma], Bull Cancer, vol.94, pp.232-272, 2007.

C. Boccaccio and P. M. Comoglio, Invasive growth: a MET-driven genetic programme for cancer and stem cells, Nature Reviews Cancer, vol.16, issue.8, pp.637-682, 2006.
DOI : 10.1038/nrc1912

A. D. Bradshaw, The role of SPARC in extracellular matrix assembly, Journal of Cell Communication and Signaling, vol.54, issue.3-4, pp.3-4, 2009.
DOI : 10.1007/s12079-009-0062-6

J. Briggs and S. Chamboredon, Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells, Oncogene, vol.21, issue.46, pp.7077-91, 2002.
DOI : 10.1038/sj.onc.1205857

URL : https://hal.archives-ouvertes.fr/ensl-00179713

S. Chandrasekhar and A. K. Harvey, Osteonectin/SPARC is a product of articular chondrocytes/cartilage and is regulated by cytokines and growth factors, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1221, issue.1, pp.7-14, 1994.
DOI : 10.1016/0167-4889(94)90209-7

S. Cheetham and M. J. Tang, SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2???deoxycytidine to increase SPARC expression and improve therapy response, British Journal of Cancer, vol.159, issue.11, pp.1810-1819, 2008.
DOI : 10.1038/sj.onc.1204970

J. Chen and D. Shi, Targeting SPARC by lentivirus-mediated RNA interference inhibits cervical cancer cell growth and metastasis, BMC Cancer, vol.419, issue.2, p.464, 2012.
DOI : 10.1016/j.neulet.2007.04.037

C. Chetty and R. Dontula, SPARC expression induces cell cycle arrest via STAT3 signaling pathway in medulloblastoma cells, Biochemical and Biophysical Research Communications, vol.417, issue.2, pp.874-883, 2012.
DOI : 10.1016/j.bbrc.2011.12.065

J. C. Cheville and H. Zincke, pT1 clear cell renal cell carcinoma, Cancer, vol.32, issue.8, pp.2180-2184, 2002.
DOI : 10.1002/cncr.10433

A. Chlenski and S. Liu, Neuroblastoma Angiogenesis Is Inhibited with a Folded Synthetic Molecule Corresponding to the Epidermal Growth Factor-Like Module of the Follistatin Domain of SPARC, Cancer Research, vol.64, issue.20, pp.7420-7425, 2004.
DOI : 10.1158/0008-5472.CAN-04-2141

A. Chlenski and S. Liu, SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis, Cancer Res, vol.62, issue.24, pp.7357-63, 2002.

J. L. Conant and Z. Peng, Sarcomatoid renal cell carcinoma is an example of epithelial-mesenchymal transition, Journal of Clinical Pathology, vol.64, issue.12, pp.1088-92, 2011.
DOI : 10.1136/jclinpath-2011-200216

E. Corgna and M. Betti, Renal cancer, Critical Reviews in Oncology/Hematology, vol.64, issue.3, pp.247-62, 2007.
DOI : 10.1016/j.critrevonc.2007.04.007

J. F. Dimartino and N. J. Lacayo, Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein, Leukemia, vol.95, issue.3, pp.426-458, 2006.
DOI : 10.1002/jcb.240490310

M. Dziadek and M. Paulsson, Purification and tissue distribution of a small protein (BM-40) extracted from a basement membrane tumor, European Journal of Biochemistry, vol.23, issue.2, pp.455-64, 1986.
DOI : 10.1083/jcb.96.1.124

J. N. Eble and G. Sauter, Pathology and genetics of tumors of the urinary system and male genital organs, IARC, 2004.

J. Edeline and C. Vigneau, [Signalling pathways in renal-cell carcinoma: from the molecular biology to the future therapy], Bull Cancer, vol.97, pp.5-15, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00480057

J. I. Everitt and C. L. Walker, Altered expression of transforming growth factor-??: An early event in renal cell carcinoma development, Molecular Carcinogenesis, vol.35, issue.3, pp.213-222, 1997.
DOI : 10.1002/(SICI)1098-2744(199707)19:3<213::AID-MC9>3.0.CO;2-E

N. Fenouille and A. Puissant, Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC, Cancer Research, vol.70, issue.23, pp.9659-70, 2010.
DOI : 10.1158/0008-5472.CAN-10-2034

N. Fenouille and A. Puissant, SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival, Oncogene, vol.62, issue.49, pp.4887-900, 2011.
DOI : 10.1038/ncb1101-973

N. Fenouille and M. Tichet, The Epithelial-Mesenchymal Transition (EMT) Regulatory Factor SLUG (SNAI2) Is a Downstream Target of SPARC and AKT in Promoting Melanoma Cell Invasion, PLoS ONE, vol.12, issue.7, p.40378, 2012.
DOI : 10.1371/journal.pone.0040378.s005

URL : https://hal.archives-ouvertes.fr/hal-01068398

N. Ferrara and H. P. Gerber, The biology of VEGF and its receptors, Nature Medicine, vol.9, issue.6, pp.669-76, 2003.
DOI : 10.1038/nm0603-669

A. Francki and E. H. Sage, SPARC and the Kidney Glomerulus Matricellular Proteins Exhibit Diverse Functions under Normal and Pathological Conditions, Trends in Cardiovascular Medicine, vol.11, issue.1, pp.32-39, 2001.
DOI : 10.1016/S1050-1738(01)00081-0

S. A. Fuhrman and L. C. Lasky, Prognostic significance of morphologic parameters in renal cell carcinoma, The American Journal of Surgical Pathology, vol.6, issue.7, pp.655-63, 1982.
DOI : 10.1097/00000478-198210000-00007

T. Funakoshi and C. H. Lee, A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma, Cancer Treatment Reviews, vol.40, issue.4, pp.533-580, 2014.
DOI : 10.1016/j.ctrv.2013.11.008

M. A. Gieseg and T. Cody, Expression profiling of human renal carcinomas with functional taxonomic analysis, BMC Bioinformatics, vol.3, issue.1, p.26, 2002.
DOI : 10.1186/1471-2105-3-26

D. T. Gilmour and G. J. Lyon, Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens, The EMBO Journal, vol.17, issue.7, pp.1860-70, 1998.
DOI : 10.1093/emboj/17.7.1860

S. Gobbo and J. N. Eble, Clear Cell Papillary Renal Cell Carcinoma, The American Journal of Surgical Pathology, vol.32, issue.8, pp.1239-1284, 2008.
DOI : 10.1097/PAS.0b013e318164bcbb

W. A. Golembieski and S. L. Thomas, HSP27 mediates SPARC-induced changes in glioma morphology, migration, and invasion, Glia, vol.155, issue.10, pp.1061-75, 2008.
DOI : 10.1002/glia.20679

W. J. Gradishar and S. Tjulandin, Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil???Based Paclitaxel in Women With Breast Cancer, Journal of Clinical Oncology, vol.23, issue.31, pp.7794-803, 2005.
DOI : 10.1200/JCO.2005.04.937

H. Huang and S. Colella, Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays, Cancer Res, vol.60, issue.24, pp.6868-74, 2000.

J. D. Hunt and O. L. Van-der-hel, Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies, International Journal of Cancer, vol.128, issue.1, pp.101-109, 2005.
DOI : 10.1002/ijc.20618

V. V. Iakovlev and M. Gabril, Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study, Laboratory Investigation, vol.7, issue.1, pp.46-56, 2012.
DOI : 10.1111/j.1464-410X.2006.06006.x

Y. Ikuta and T. Nakatsura, Highly Sensitive Detection of Melanoma at an Early Stage Based on the Increased Serum Secreted Protein Acidic and Rich in Cysteine and Glypican-3 Levels, Clinical Cancer Research, vol.11, issue.22, pp.8079-88, 2005.
DOI : 10.1158/1078-0432.CCR-05-1074

J. R. Infante and H. Matsubayashi, Peritumoral Fibroblast SPARC Expression and Patient Outcome With Resectable Pancreatic Adenocarcinoma, Journal of Clinical Oncology, vol.25, issue.3, pp.319-344, 2007.
DOI : 10.1200/JCO.2006.07.8824

M. Inoue and S. Senju, Identification of SPARC as a candidate target antigen for immunotherapy of various cancers, International Journal of Cancer, vol.8, issue.6, pp.1393-403, 2010.
DOI : 10.1002/ijc.25160

K. A. Kelly and J. R. Allport, SPARC is a VCAM-1 counter-ligand that mediates leukocyte transmigration, Journal of Leukocyte Biology, vol.81, issue.3, pp.748-56, 2007.
DOI : 10.1189/jlb.1105664

S. K. Khoo and M. Bradley, Birt-Hogg-Dub?? syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2, Oncogene, vol.20, issue.37, pp.5239-5281, 2001.
DOI : 10.1038/sj.onc.1204703

T. Klatte and A. J. Pantuck, Prognostic Factors for Renal Cell Carcinoma With Tumor Thrombus Extension, The Journal of Urology, vol.178, issue.4, pp.1189-95, 2007.
DOI : 10.1016/j.juro.2007.05.134

K. Kondo, W. G. Kaelin, and J. , The von Hippel???Lindau Tumor Suppressor Gene, Experimental Cell Research, vol.264, issue.1, pp.117-142, 2001.
DOI : 10.1006/excr.2000.5139

K. Kos and J. P. Wilding, SPARC: a key player in the pathologies associated with obesity and diabetes, Nature Reviews Endocrinology, vol.10, issue.4, pp.225-260, 2010.
DOI : 10.1038/nrendo.2010.18

M. I. Koukourakis and A. Giatromanolaki, Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients, Cancer Res, vol.63, issue.17, pp.5376-80, 2003.

C. Kupprion and K. Motamed, SPARC (BM-40, Osteonectin) Inhibits the Mitogenic Effect of Vascular Endothelial Growth Factor on Microvascular Endothelial Cells, Journal of Biological Chemistry, vol.273, issue.45, pp.29635-29675, 1998.
DOI : 10.1074/jbc.273.45.29635

J. Kzhyshkowska and G. Workman, Novel Function of Alternatively Activated Macrophages: Stabilin-1-Mediated Clearance of SPARC, The Journal of Immunology, vol.176, issue.10, pp.5825-5857, 2006.
DOI : 10.4049/jimmunol.176.10.5825

T. F. Lane and E. H. Sage, Functional mapping of SPARC: peptides from two distinct Ca+(+)-binding sites modulate cell shape, The Journal of Cell Biology, vol.111, issue.6, pp.3065-76, 1990.
DOI : 10.1083/jcb.111.6.3065

T. F. Lane and E. H. Sage, The biology of SPARC, a protein that modulates cell-matrix interactions, FASEB J, vol.8, issue.2, pp.163-73, 1994.

C. P. Lau and R. T. Poon, SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma, The Journal of Pathology, vol.166, issue.4, pp.459-68, 2006.
DOI : 10.1002/path.2068

M. F. Ledda and S. Adris, Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells, Nature Medicine, vol.263, issue.2, pp.171-177, 1997.
DOI : 10.1016/0167-5699(96)80563-9

F. Levi and J. Ferlay, The changing pattern of kidney cancer incidence and mortality in Europe, BJU International, vol.353, issue.8, pp.949-58, 2008.
DOI : 10.1111/j.1464-410X.2008.07451.x

H. C. Lien and Y. H. Hsiao, Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial???mesenchymal transition, Oncogene, vol.10, issue.57, pp.7859-71, 2007.
DOI : 10.1038/ncb1173

B. Ljungberg and S. C. Campbell, The Epidemiology of Renal Cell Carcinoma, European Urology, vol.60, issue.4, pp.615-636, 2011.
DOI : 10.1016/j.eururo.2011.06.049

E. N. Maina and M. R. Morris, Identification of novel VHL target genes and relationship to hypoxic response pathways, Oncogene, vol.2, issue.28, pp.4549-58, 2005.
DOI : 10.1038/sj.onc.1208649

A. Marsaud and B. Dadone, Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases, Genes, Chromosomes and Cancer, vol.65, issue.6
DOI : 10.1002/gcc.22248

D. Massi and A. Franchi, Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas, Human Pathology, vol.30, issue.3, pp.339-383, 1999.
DOI : 10.1016/S0046-8177(99)90014-X

T. M. Mekhail and R. M. Abou-jawde, Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.23, issue.4, pp.832-873, 2005.
DOI : 10.1200/JCO.2005.05.179

A. J. Minn and G. P. Gupta, Genes that mediate breast cancer metastasis to lung, Nature, vol.436, issue.7050, pp.518-542, 2005.
DOI : 10.1038/nature03799

C. Mrstik and J. Salamon, Microscopic venous infiltration as predictor of relapse in renal cell carcinoma, J Urol, vol.148, issue.2, pp.271-275, 1992.

G. P. Nagaraju and D. Sharma, Anti-cancer role of SPARC, an inhibitor of adipogenesis, Cancer Treatment Reviews, vol.37, issue.7, pp.559-66, 2011.
DOI : 10.1016/j.ctrv.2010.12.001

G. S. Palapattu and A. J. Pantuck, Collecting System Invasion In Renal Cell Carcinoma: Impact on Prognosis And Future Staging Strategies, The Journal of Urology, vol.170, issue.3, pp.768-72, 2003.
DOI : 10.1097/01.ju.0000082580.13597.a2

V. Paradis and S. Ferlicot, CD44 IS AN INDEPENDENT PROGNOSTIC FACTOR IN CONVENTIONAL RENAL CELL CARCINOMAS, The Journal of Urology, vol.161, issue.6, pp.1984-1991, 1999.
DOI : 10.1016/S0022-5347(05)68869-6

J. J. Patard and H. Baumert, Recommandations en onco-urologie 2013 du CCAFU: Cancer du rein, Progr??s en Urologie, vol.23, issue.2, pp.177-204, 2013.
DOI : 10.1016/S1166-7087(13)70055-1

URL : https://hal.archives-ouvertes.fr/hal-01120359

O. L. Podhajcer and L. G. Benedetti, The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host, Cancer and Metastasis Reviews, vol.20, issue.3, pp.691-705, 2008.
DOI : 10.1007/s10555-008-9146-7

P. L. Porter and E. H. Sage, Distribution of SPARC in normal and neoplastic human tissue., Journal of Histochemistry & Cytochemistry, vol.43, issue.8, pp.791-800, 1995.
DOI : 10.1177/43.8.7622842

F. Prada and L. G. Benedetti, SPARC Endogenous Level, rather than Fibroblast-Produced SPARC or Stroma Reorganization Induced by SPARC, Is Responsible for Melanoma Cell Growth, Journal of Investigative Dermatology, vol.127, issue.11, pp.2618-2646, 2007.
DOI : 10.1038/sj.jid.5700962

E. W. Raines and T. F. Lane, The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors., Proceedings of the National Academy of Sciences, vol.89, issue.4, pp.1281-1286, 1992.
DOI : 10.1073/pnas.89.4.1281

X. Rebillard and P. Grosclaude, Projection de l???incidence et de la mortalit?? par cancer urologique en France en 2012, Progr??s en Urologie, vol.23, issue.2, pp.57-65, 2013.
DOI : 10.1016/S1166-7087(13)70047-2

F. Réseau and S. , Estimation nationale de l'incidence et de la mortalité par cancer en France entre, Institut bational du Cancer, 1980.

J. N. Rich and C. Hans, Gene Expression Profiling and Genetic Markers in Glioblastoma Survival, Cancer Research, vol.65, issue.10, pp.4051-4059, 2005.
DOI : 10.1158/0008-5472.CAN-04-3936

S. Richard and C. Ladroue, Genetics and angiogenesis: the example of von Hippel-Lindau disease], Bull Cancer, vol.94, pp.170-179, 2007.

N. Rioux-leclercq and B. Turlin, Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma, Urology, vol.55, issue.4, pp.501-506, 2000.
DOI : 10.1016/S0090-4295(99)00550-6

L. B. Rivera and A. D. Bradshaw, The regulatory function of SPARC in vascular biology, Cellular and Molecular Life Sciences, vol.14, issue.1, pp.3165-73, 2011.
DOI : 10.1007/s00018-011-0781-8

G. Robert and C. Gaggioli, SPARC Represses E-Cadherin and Induces Mesenchymal Transition during Melanoma Development, Cancer Research, vol.66, issue.15, pp.7516-7539, 2006.
DOI : 10.1158/0008-5472.CAN-05-3189

URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.322.8079

D. M. Sabatini, mTOR and cancer: insights into a complex relationship, Nature Reviews Cancer, vol.10, issue.9, pp.729-763, 2006.
DOI : 10.1038/nrc1974

H. Sage and C. Johnson, Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture, J Biol Chem, vol.259, issue.6, pp.3993-4007, 1984.

N. Said and K. Motamed, Absence of Host-Secreted Protein Acidic and Rich in Cysteine (SPARC) Augments Peritoneal Ovarian Carcinomatosis, The American Journal of Pathology, vol.167, issue.6, pp.1739-52, 2005.
DOI : 10.1016/S0002-9440(10)61255-2

N. Said and M. J. Socha, Normalization of the Ovarian Cancer Microenvironment by SPARC, Molecular Cancer Research, vol.5, issue.10, pp.1015-1045, 2007.
DOI : 10.1158/1541-7786.MCR-07-0001

N. Sakai and M. Baba, SPARC expression in primary human renal cell carcinoma: Upregulation of SPARC in sarcomatoid renal carcinoma, Human Pathology, vol.32, issue.10, pp.1064-70, 2001.
DOI : 10.1053/hupa.2001.28244

N. Sato and N. Fukushima, Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays, Cancer Res, vol.63, issue.13, pp.3735-3777, 2003.

C. Schultz and N. Lemke, Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo, Cancer Res, vol.62, issue.21, pp.6270-6277, 2002.

T. Seno and H. Harada, Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas, International Journal of Oncology, vol.34, issue.3, pp.707-722, 2009.
DOI : 10.3892/ijo_00000197

U. T. Shankavaram and D. L. Dewitt, Regulation of human monocyte matrix metalloproteinases by SPARC, Journal of Cellular Physiology, vol.732, issue.3, pp.327-361, 1997.
DOI : 10.1002/(SICI)1097-4652(199712)173:3<327::AID-JCP4>3.0.CO;2-P

Q. Shi and S. Bao, Secreted Protein Acidic, Rich in Cysteine (SPARC), Mediates Cellular Survival of Gliomas through AKT Activation, Journal of Biological Chemistry, vol.279, issue.50, pp.52200-52209, 2004.
DOI : 10.1074/jbc.M409630200

Q. Shi and S. Bao, Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases, Oncogene, vol.159, issue.28, pp.4084-94, 2007.
DOI : 10.1038/sj.onc.1210181

D. J. Smit and B. B. Gardiner, Osteonectin downregulates E-cadherin, induces Osteopontin and Focal adhesion kinase activity stimulating an invasive melanoma phenotype, International Journal of Cancer, vol.5, issue.12, pp.2653-60, 2007.
DOI : 10.1002/ijc.23039

L. Sobin and M. Gospodarowicz, TNM Classification des tumeurs malignes Septième Edition, 2010.

M. J. Socha and N. Said, Aberrant Promoter Methylation of Sparc in Ovarian Cancer, Neoplasia, vol.11, issue.2, pp.126-161, 2009.
DOI : 10.1593/neo.81146

J. R. Srigley and B. Delahunt, The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia, The American Journal of Surgical Pathology, vol.37, issue.10, pp.1469-89, 2013.
DOI : 10.1097/PAS.0b013e318299f2d1

M. Suzuki and C. Hao, Aberrant methylation of SPARC in human lung cancers, British Journal of Cancer, vol.159, issue.5, pp.942-950, 2005.
DOI : 10.1002/cncr.11368

F. Taghizadeh and M. J. Tang, Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy, Molecular Cancer Therapeutics, vol.6, issue.1, pp.309-326, 2007.
DOI : 10.1158/1535-7163.MCT-06-0517

I. T. Tai and M. Dai, Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy, Journal of Clinical Investigation, vol.115, issue.6, pp.1492-502, 2005.
DOI : 10.1172/JCI23002

I. T. Tai and M. J. Tang, SPARC in cancer biology: Its role in cancer progression and potential for therapy, Drug Resistance Updates, vol.11, issue.6, pp.231-277, 2008.
DOI : 10.1016/j.drup.2008.08.005

M. J. Tang and I. T. Tai, A Novel Interaction between Procaspase 8 and SPARC Enhances Apoptosis and Potentiates Chemotherapy Sensitivity in Colorectal Cancers, Journal of Biological Chemistry, vol.282, issue.47, pp.34457-67, 2007.
DOI : 10.1074/jbc.M704459200

J. D. Termine and H. K. Kleinman, Osteonectin, a bone-specific protein linking mineral to collagen, Cell, vol.26, issue.1, pp.99-105, 1981.
DOI : 10.1016/0092-8674(81)90037-4

C. Terrone and C. Cracco, Prognostic Value of the Involvement of the Urinary Collecting System in Renal Cell Carcinoma, European Urology, vol.46, issue.4, pp.472-478, 2004.
DOI : 10.1016/j.eururo.2004.07.006

J. P. Thiery, Epithelial???mesenchymal transitions in tumour progression, Nature Reviews Cancer, vol.59, issue.6, pp.442-54, 2002.
DOI : 10.1038/nrc822

M. Tichet and N. Fenouille, Tumour-derived SPARC drives vascular permeability, tumour cell extravasation and metastasis via endothelial VCAM1 signalling, Nature Communications

I. P. Tomlinson and N. A. Alam, Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer, Nature Genetics, vol.30, issue.4, pp.406-416, 2002.
DOI : 10.1038/ng849

R. Tripathi and R. Mishra, Interaction of Pax6 with SPARC and p53 in Brain of Mice Indicates Smad3 Dependent Auto-regulation, Journal of Molecular Neuroscience, vol.203, issue.3, pp.397-403, 2010.
DOI : 10.1007/s12031-010-9334-0

L. D. Truong and S. S. Shen, Immunohistochemical diagnosis of renal neoplasms, Arch Pathol Lab Med, vol.135, issue.1, pp.92-109, 2011.

H. Van-poppel and H. Vandendriessche, Microscopic Vascular Invasion is the Most Relevant Prognosticator After Radical Nephrectomy for Clinically Nonmetastatic Renal Cell Carcinoma, The Journal of Urology, vol.158, issue.1, pp.45-54, 1997.
DOI : 10.1097/00005392-199707000-00013

I. Vivanco and C. L. Sawyers, The phosphatidylinositol 3-Kinase???AKT pathway in human cancer, Nature Reviews Cancer, vol.2, issue.7, pp.489-501, 2002.
DOI : 10.1038/nrc839

V. Hoff, D. D. , and T. Ervin, Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine, New England Journal of Medicine, vol.369, issue.18, pp.1691-703, 2013.
DOI : 10.1056/NEJMoa1304369

Y. Wang and Q. Yu, Survey of Differentially Methylated Promoters in Prostate Cancer Cell Lines, Neoplasia, vol.7, issue.8, pp.748-60, 2005.
DOI : 10.1593/neo.05289

G. Watkins and A. Douglas-jones, Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes, Prostaglandins, Leukotrienes and Essential Fatty Acids, vol.72, issue.4, pp.267-72, 2005.
DOI : 10.1016/j.plefa.2004.12.003

J. L. Wrana and T. Kubota, . Comparisons with expression of SPARC (secreted acidic cysteine-rich protein), Biochemical Journal, vol.273, issue.3, pp.523-554, 1991.
DOI : 10.1042/bj2730523

J. L. Wrana and C. M. Overall, Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen, European Journal of Biochemistry, vol.9, issue.2, pp.519-547, 1991.
DOI : 10.1016/0168-9525(88)90074-1

E. Yang and H. J. Kang, Frequent inactivation of SPARC by promoter hypermethylation in colon cancers, International Journal of Cancer, vol.109, issue.3, pp.567-75, 2007.
DOI : 10.1002/ijc.22706

G. K. Yiu and W. Y. Chan, SPARC (Secreted Protein Acidic and Rich in Cysteine) Induces Apoptosis in Ovarian Cancer Cells, The American Journal of Pathology, vol.159, issue.2, pp.609-631, 2001.
DOI : 10.1016/S0002-9440(10)61732-4